Gabriel Tremblay, DBA, MSc, BA Economics

Gabriel Tremblay is a health economist and health technology commercialization expert with 16 years experience.

Gabriel is an applied economist specializing in health economic studies and health technology assessments, with over sixteen years of experience in the pharmaceutical industry and consulting. His primary focus is on health economics and reimbursment submissions, cost-effectiveness analysis, economic evaluation, and comparative-effectiveness research for drugs and medical technologies. He has conducted over 150 health economics and health technology assessment analyses and completed more than 130 economic submissions to payers in 40 different countries.

Currently, Gabriel specializes in health technology assessment, reimbursement, and submission consulting for drugs, medical devices, cell therapies, and hospital technologies. He primarily collaborates with biotechs and pharmaceutical companies trying to identify and demonstrate their economic value. He supports companies as consultant or investor when they are preparing for the commercialization process to secure reimbursements from public or private payers. Additionally, he has actively participated as an investor in supporting high-potential biotechs.

Gabriel has worked extensively in the pharmaceutical industry at both global and local levels, as well as for multiple consulting agencies in Health Economics and Outcomes Research. In 2016, Gabriel co-founded Purple Squirel Economics, which was later acquired by Cytel Inc. He subsequently served as Vice President of Health Economics at Cytel for many years. Gabriel holds a Doctorate in Business Administration specializing in healthcare decision making for health technology assessment from BSI Luxembourg and Lyon University, an MSc in health economics from HEC Montréal, and a BA in Economics.